Merck details PhII TIGIT/PD-1 fail in lung cancer – Endpoints News

by

  1. Merck details PhII TIGIT/PD-1 fail in lung cancer Endpoints News
  2. Merck stock falls as cancer trial for Keytruda combo fails Seeking Alpha
  3. Merck’s lung cancer drug combo fails trial in setback for new therapy class Reuters
  4. Merck & Co. digs into TIGIT fail, sharing survival data from phase 2 lung cancer trial FierceBiotech
  5. Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire

Read original article here

Leave a Comment